However, the company announced mid-last-week that while the special virtual-only meeting of shareholders where a majority voted in favor of the company’s domestication to Delaware, shareholders failed to complete a 2/3 vote in favor of it, and the localization will therefore not happen.
Covered by approximately 70 granted and pending patents, the TRUFORMA diagnostic platform uses Qorvo’s (NASDAQ: QRVO) developed Bulk Acoustic Wave technology to provide a non-optical and fluorescence-free point-of-care detection method. This technology is widely used in the most advanced radar and communication systems globally and has proven extremely reliable and precise. Sales of TRUFORMA are expected to begin on March 30, 2021, according to Zomedica.
Read More
